Riskpilot← Back to searchSign inGet full accessBIOSTRAT BIOTECH CONSULTING ApS
APSActiveCVR 30814622Lindevej 5Business and other management consultancy activities · NACE 7020Est. 20071 employees
Revenue 2024
DKK -287K
+60% vs 2023
EBITDA margin
100.0%
+72% vs 2023
Equity ratio
97.9%
Financial strength
Net profit 2024
DKK 18,6M
+415% vs 2023
| Revenue | DKK -287K | +60% |
| EBITDA | DKK -287K | +72% |
| Net profit | DKK 18,6M | +415% |
| Total assets | DKK 61,7M | -6% |
| Equity | DKK 60,4M | -7% |
| Employees | 1 | — |
Legal name
BIOSTRAT BIOTECH CONSULTING ApS
CVR number
30814622
Legal form
Anpartsselskab
NACE code
7020 · Business and other management consultancy activities
Founded
3. september 2007
Share capital
DKK 125.000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af direktøren.
Company purpose
Selskabets formål er at fungere som holdingselskab, investering i og formuepleje af værdi-papirer samt salg af konsulentydelser og hermed efter ledelsens skøn beslægtet virksomhed.
Address
Lindevej 5
Phone
+4525462580
Email
nhn@nhn.dk
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 139 | 480 | 337 | 85 | -54 | -229 | 1.155 | 482 | 571 | 99 | -274 | -180 | -287 |
| Staff expenses | -2 | -9 | -0 | -0 | -119 | -506 | -771 | -266 | -400 | -0 | -500 | -850 | -0 |
| EBITDA | 137 | 471 | 337 | 85 | -173 | -735 | 385 | 217 | 171 | 99 | -774 | -1.030 | -287 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | 137 | 471 | 337 | 85 | -173 | -735 | 385 | 217 | 171 | 99 | -774 | -1.030 | -287 |
| Net financials | 41 | 38 | -536 | 7.087 | 381 | 97 | 1.969 | 229 | 128.601 | -65.349 | 15.834 | -4.878 | 20.157 |
| Profit before tax | 177 | 509 | -199 | 7.173 | 208 | -638 | 2.354 | 446 | 128.772 | -65.250 | 15.061 | -5.908 | 19.870 |
| Tax | 43 | 128 | 89 | 141 | -137 | -94 | 43 | 101 | 33 | -6.419 | 6.467 | -8 | 1.263 |
| Net profit | 134 | 381 | -288 | 7.031 | 345 | -544 | 2.311 | 344 | 128.739 | -58.831 | 8.593 | -5.899 | 18.607 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 1.456 | 1.542 | 1.864 | 8.081 | 8.322 | 7.858 | 5.392 | 5.163 | 133.707 | 69.537 | 73.404 | 65.622 | 61.702 |
| Equity | 1.012 | 1.297 | 910 | 7.941 | 8.286 | 7.639 | 4.700 | 4.936 | 133.325 | 69.494 | 73.087 | 65.188 | 60.395 |
| Long-term debt | 0 | 0 | 500 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 445 | 246 | 455 | 140 | 36 | 220 | 693 | 227 | 382 | 43 | 317 | 434 | 1.306 |
| Total debt | 445 | 246 | 955 | 140 | 36 | 220 | 693 | 227 | 382 | 43 | 317 | 434 | 1.306 |
EBITDA margin
-28694900.0%
This company
15.8%
Market median
-181613391% vs market
20122024
Equity ratio
97.9%
This company
38.2%
Market median
+156% vs market
20122024
Return on equity
30.8%
This company
18.4%
Market median
+67% vs market
20122024
Net profit margin
1860730400.0%
This company
8.1%
Market median
+22971980147% vs market
20122024
Asset turnover
-0.00×
This company
1.12×
Market median
-100% vs market
20122024
Debt / equity
0.02×
This company
0.62×
Market median
+97% vs market
20122024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
No data on file.
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100.0% | 100.0% | 2007 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
BIOSTRAT BIOTECH CONSULTING ApS 
Copenhagen United 5 ApSBoard members of BIOSTRAT BIOTECH CONSULTING ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|